Ovarian Cancer

For women's cancers, where you're treated matters

(HealthDay)—Where you're treated for ovarian or other gynecologic cancers makes a difference. Women with these conditions live more than a year longer on average if they're treated at hospitals that deal ...

Mar 24, 2014
popularity 5 / 5 (1) | comments 0

BRCAPRO model underestimates BRCA1/2 mutation risk

(HealthDay)—Use of the BRCAPRO model for assessment of the likelihood of having a germline BRCA1/BRCA2 mutation, based on age, ethnicity, and family history, may underestimate the risk of mutations, ac ...

Mar 21, 2014
popularity not rated yet | comments 0

Scientists use laying hens to study fibroid tumors

An estimated 70 percent of women in the United States develop fibroid tumors in the uterus by age 50, and while the noncancerous tumors cause no symptoms for the majority of those women, they make life miserable ...

Mar 06, 2014
popularity not rated yet | comments 0

Latest Spotlight News

Stroke damage mechanism identified

Researchers have discovered a mechanism linked to the brain damage often suffered by stroke victims—and are now searching for drugs to block it.

Berberine compound may play role in treating obesity

(Medical Xpress)—Weight-gain warnings are especially uncomfortable during holiday seasons with all the oversized and double helpings of calorie-rich pies, creamy dips and savory holiday stuffings. Nonetheless, ...

"Body recognition" compares with fingerprint ID

(Medical Xpress)—University of Adelaide forensic anatomy researchers are making advances in the use of "body recognition" for criminal and missing persons cases, to help with identification when a face ...

Some people may be pre-wired to be bilingual

(HealthDay)—Some people's brains seem pre-wired to acquire a second language, new research suggests. But anyone who tries to move beyond their mother tongue will likely gain a brain boost, the small study ...

Ebola vaccine promising in first human trials

Researchers say they're a step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.